Genetic testing is an important part of the diagnosis process for transthyretin cardiac amyloidosis (ATTR-CM). It’s not only key to managing your care but also helps you determine whether others in ...

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) -Acoramidis mitigated the rise in NT-proBNP through Month ...

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p -Acoramidis mitigated the rise in NT-proBNP through Month 54 to an extent not seen in the era ...

− Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Patients More than Ten Years ...

Alnylam has big ambitions for Amvuttra. But despite an explosive transthyretin amyloid cardiomyopathy (ATTR-CM) launch in 2025, three questions remain: potential upcoming competition from AstraZeneca ...

Experts weigh prior authorization, step therapy, and 12‑month coverage to balance access and cost for high‑value long‑term therapies. This episode, titled ‘Navigating Benefit Design and Utilization ...

Good morning, everyone, and thank you for joining us today. I'm Tolga Tanguler, Chief Commercial Officer at Alnylam, and I'm thrilled to be hosting today's webinar to update you on our leadership ...

Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Kevin M. Alexander, MD, eagerly awaits the presentation of new amyloid dataat the 2026 ACC meeting in New Orleans and is especially interested in the subgroup analyses from the ATTRibute-CM and HELIOS ...

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Prothena has now earned $150 million to date of the $1.2 billion total ...